Table 1.
Baseline characteristics of the included patients.
| Variable | All patients (n = 908) |
|---|---|
| Age in years, median (IQR) | 67 (60–75) |
| Sex, n (%) | |
| Female | 176 (19.4) |
| Male | 732 (80.6) |
| Etiology, n (%) | |
| No cirrhosis | 103 (11.3) |
| Alcohol | 360 (39.7) |
| Viral | 270 (29.7) |
| Other | 175 (19.3) |
| Child-Pugh stage, n (%) | |
| No cirrhosis | 103 (11.3) |
| A | 499 (55.0) |
| B | 306 (33.7) |
| BCLC stage, n (%) | |
| 0 | 14 (1.5) |
| A | 272 (30.0) |
| B | 490 (54.0) |
| C | 132 (14.5) |
| Size of the largest lesion in mm, max (IQR) | 40 (27–64) |
| Number of lesions, median (IQR) | 2 (1–4) |
| Albumin level, median (IQR) | 36 (31–40) |
| Bilirubin level, median (IQR) | 1.1 (0.7–1.8) |
| Platelet count, median (IQR) | 127 (85–192) |
| AST level, median (IQR) | 60 (41–91) |
| ALT level, median (IQR) | 40 (27–62) |
| INR, median (IQR) | 1.1 (1.1–1.2) |
| AFP level, median (IQR) | 20.9 (5.7–348.5) |
BCLC, Barcelona Clinic Liver Cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha fetoprotein